首页> 外文期刊>Case Reports in Genetics >NovelSMAD3Mutation in a Patient with Hypoplastic Left Heart Syndrome with Significant Aortic Aneurysm
【24h】

NovelSMAD3Mutation in a Patient with Hypoplastic Left Heart Syndrome with Significant Aortic Aneurysm

机译:伴有明显主动脉瘤的发育不良左心综合征患者的新型SMAD3突变

获取原文
       

摘要

Aneurysms-osteoarthritis syndrome (AOS) caused by haploinsufficiency ofSMAD3is a recently described cause of syndromic familial thoracic aortic aneurysm and dissection (TAAD). We identified a novelSMAD3mutation in a patient with hypoplastic left heart syndrome (HLHS) who developed progressive aortic aneurysm requiring surgical replacement of the neoaortic root, ascending aorta, and proximal aortic arch. Family screening for the mutation revealed that his father, who has vascular and skeletal features of AOS, and his brother, who is asymptomatic, also have the pathogenic mutation. This is the first case report of aSMAD3mutation in a patient with hypoplastic left heart syndrome. This case highlights the importance of genetic testing for known causes of aneurysm in patients with congenital heart disease who develop aneurysmal disease as it may significantly impact the management of those patients and their family members.
机译:由SMAD3单倍剂量不足引起的动脉瘤-骨关节炎综合征(AOS)是最近描述的家族性家族性胸主动脉瘤和夹层动脉瘤(TAAD)的病因。我们在患有发育不良的左心综合征(HLHS)的患者中发现了一种新型SMAD3突变,该患者发展为进行性主动脉瘤,需要手术置换新主动脉根,升主动脉和主动脉近端弓。家庭对该突变进行了筛查,发现他的父亲(具有AOS的血管和骨骼特征)和他的兄弟(无症状)也具有致病性突变。这是患有增生性左心综合征的患者中aSMAD3突变的第一例病例报告。该案例强调了基因检测对先天性心脏病患者(发生动脉瘤疾病)的已知动脉瘤病因进行基因检测的重要性,因为这可能显着影响这些患者及其家人的管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号